What Did The Market Misjudge About GoodRx?

If you had put money into GoodRx on 1 October 2025 and simply held on, the outcome would have been painful. Holding GoodRx over the past year would have meant a 27.3% loss, including dividends. That result sits awkwardly against bullish expectations for mid single digit revenue growth, a profit margin target above 11.0%, and a P/E reset to 18.2x within three years. If those assumptions were on the table at the start, what did that original investment case miss about GoodRx’s risks and dependencies?

This theme extends beyond GoodRx. See which of 35 healthcare AI stocks may still merit a closer look.

The Two Stories Investors Were Really Buying With GoodRx

The shares cost US$5.03 at the start of the period, and anyone looking at GoodRx then had to choose between two very different but plausible stories.

The bullish view argued that digital health adoption would widen GoodRx’s opportunity. Under that view, a Fair Value of US$5.37, the price implied if its assumptions played out, rested on revenue growth of 5.8% and profit margins rising to 11.2%, with a future P/E of 18.2x.

The bearish narrative saw more pressure from regulation and tech rivals. That perspective put Fair Value at US$3.40 and focused on risks such as government drug pricing reforms that could shrink discounts and reduce user traffic, while still assuming 4.0% revenue growth and a 10.2% margin with a 13.3x P/E.

What The Results Put To The Test For GoodRx

The Companion Family Plan launch and the Paytient partnership both pointed in the direction the bullish GoodRx story wanted, with more subscription reach and deeper employer access. The results pulled the other way. Revenue slipped from US$203.07m to US$200.41m and net margin moved from 6.3% to 4.3%. Taken together, the evidence cut both ways.

The key assumption was that digital offerings would quickly lift both scale and profitability. When you assess another healthcare platform, track whether new products show up in higher revenue and a sturdier margin, not just in press releases.

What GoodRx’s Lower Price Now Asks You To Believe

GoodRx trades at US$3.27 today, and the selected Narrative’s Fair Value sits above that level based on its own modelling rather than any hard rule. The argument leans on GoodRx pushing deeper into pharmacy systems, subscription offers, and direct relationships so users come back more often and cost per transaction falls.

The key judgement for anyone using that Narrative is whether those integrations and memberships genuinely convert into meaningfully higher retention and transaction frequency over time.

"While analysts broadly acknowledge the benefit of digital healthcare engagement and e-commerce partnerships, they likely underappreciate GoodRx's intensifying integration into pharmacy management systems, end-to-end digitization of the prescription workflow, and expanded direct-to-consumer offerings, which can significantly elevate user retention, transaction frequency, and operating leverage, supporting outsized gains in revenue and net margins."

One Narrative disagrees with today's price. → See where this Narrative says GoodRx should trade

Before The Next Story Makes Headlines

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 43% below our estimate - secures recurring revenue by enabling encrypted satellite communications for institutional clients.
• Company 2 - 29% below our estimate - leases specialized computing capacity tailored to intensive generative artificial intelligence applications.
• Company 3 - 49% below our estimate - supports infrastructure upgrades using advanced materials that strengthen large-scale concrete structures.

Those are three of them. See the full list of 28 companies trading below our estimate →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com